ShearWaveβ’ Elastography of Breast Lesions in Chinese Patients
- Conditions
- Breast Neoplasms
- Registration Number
- NCT02226081
- Lead Sponsor
- SuperSonic Imagine
- Brief Summary
We aim to determine if adding ShearWave Elastography to a standard ultrasound breast exam can improve the characterization (classification) of breast lesions.
- Detailed Description
Chinese women are known to have denser breasts than women in Western countries. Mammography cannot find abnormalities easily in denser breasts, while breast ultrasound is not affected by density. Adding elastography, a stiffness measurement, to a breast ultrasound exam should improve the diagnosis of a lesion.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 2273
-
female
-
18 years of age or older
-
known breast lesion that has not been managed or treated
-
referred for a breast ultrasound because of a breast mass found on at least one of the following examinations:
- physical palpation
- mammography
- ultrasound exam
- MRI
- Women who are unwilling or unable to provide informed consent
- Women with breast implants
- Women who are pregnant or breastfeeding
- Women in whom all lesions are diagnostically categorized as BI-RADS 0, 1 or 6
- Women with previous ipsilateral breast surgery
- Women with no visible breast mass on ultrasound examination
- Women with axillary metastatic lymph nodes only
- Women with foreign body in the breast
- Women who are not Chinese nationality
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Increase in specificity of breast ultrasound imaging when considering stiffness measurements Within 18 months of the study start date
- Secondary Outcome Measures
Name Time Method Change of sensitivity and negative predictive value of breast ultrasound imaging when considering stiffness measurements Within 18 months of the study start date Increase in positive predictive value for biopsy of breast ultrasound when considering stiffness measurements within 18 months of the study start date
Trial Locations
- Locations (22)
Sichuan Provincial People's Hospital
π¨π³Chengdu, China
Fujian Provincial Cancer Hospital
π¨π³Fuzhou, China
1st Affiliated Hospital of PLAGH (304)
π¨π³Beijing, China
People's Liberation Army General Hospital (301)
π¨π³Beijing, China
1st Affiliated Hospital of Zhengzhou University
π¨π³Zhengzhou, China
Fudan University Cancer Center
π¨π³Shanghai, China
4th Affiliated Hospital of China Medical University
π¨π³Shenyang, China
Hefei 2nd People's Hospital
π¨π³Hefei, China
West China Hospital, Sichuan University
π¨π³Chengdu, China
Yinzhou People's Hospital
π¨π³Ningbo, China
Shengjing Hospital of China Medical University
π¨π³Shenyang, China
General Hospital of TISCO
π¨π³Taiyuan, China
Shanxi Dayi Hospital
π¨π³Taiyuan, China
Jiangsu Provincial Hospital
π¨π³Nanjing, China
1st Affiliated Hospital of Xi'an Jiaotong University
π¨π³Xi'an, China
Beijing Friendship Hospital, Capital Medical University
π¨π³Beijing, China
Affiliated Hospital of Binzhou Medical University
π¨π³Binzhou, China
Guangdong Provincial Traditional Chinese Medical Hospital
π¨π³Guangzhou, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
π¨π³Guangzhou, China
Sun-Yat Sen University Cancer Center
π¨π³Guangzhou, China
1st Affiliated Hospital of Harbin University
π¨π³Harbin, China
1st Affiliated Hospital of China Medical University
π¨π³Shenyang, China